Who are AZD5335's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): REGORAFENIB, AZD0120, CKD-828, Concurrent Lenvatinib, Lenvatinib Capsules, ABT-712.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azd5335.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

AZD5335 — Competitive Intelligence Brief

AZD5335 (AZD5335) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: FGFR1 inhibitor. Area: Oncology.

phase 3 FGFR1 inhibitor FGFR1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AZD5335 (AZD5335) — AstraZeneca. AZD5335 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant FGFR signaling in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AZD5335 TARGET	AZD5335	AstraZeneca	phase 3	FGFR1 inhibitor	FGFR1
REGORAFENIB	REGORAFENIB		marketed		RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R	2012-01-01
AZD0120	AZD0120	AstraZeneca	phase 3	FGFR1 inhibitor	FGFR1 (Fibroblast Growth Factor Receptor 1)
CKD-828	CKD-828	Chong Kun Dang Pharmaceutical	phase 3	Dual VEGFR2/FGFR1 tyrosine kinase inhibitor	VEGFR2, FGFR1
Concurrent Lenvatinib	Concurrent Lenvatinib	Sun Yat-sen University	phase 3	Multi-targeted tyrosine kinase inhibitor	FGFR1-4, VEGFR1-3, RET, KIT
Lenvatinib Capsules	Lenvatinib Capsules	National Cancer Institute, Naples	phase 3	Multi-targeted tyrosine kinase inhibitor	FGFR1-4, VEGFR1-3, RET, KIT, PDGFR-alpha
ABT-712	ABT-712	AbbVie (prior sponsor, Abbott)	phase 3	FGFR1 inhibitor	FGFR1 (Fibroblast Growth Factor Receptor 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (FGFR1 inhibitor class)

AstraZeneca · 2 drugs in this class
AbbVie (prior sponsor, Abbott) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD5335 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd5335. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab